Summary | |
---|---|
Symbol | JAM2 |
Name | junctional adhesion molecule 2 |
Aliases | VE-JAM; JAM-B; JAMB; CD322; C21orf43; PRO245; VEJAM; JAM-IT/VE-JAM; vascular endothelial junction-associated ...... |
Chromosomal Location | 21q21.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Cell junction, tight junction Cell membrane Single-pass type I membrane protein Note=Localized at tight junctions of both epithelial and endothelial cells. |
Domain |
PF07686 Immunoglobulin V-set domain |
Function |
May play a role in the processes of lymphocyte homing to secondary lymphoid organs. |
Biological Process |
GO:0007162 negative regulation of cell adhesion GO:0030198 extracellular matrix organization GO:0043062 extracellular structure organization GO:0050900 leukocyte migration |
Molecular Function |
GO:0046982 protein heterodimerization activity |
Cellular Component |
GO:0005923 bicellular tight junction GO:0043296 apical junction complex GO:0070160 occluding junction |
KEGG |
hsa04514 Cell adhesion molecules (CAMs) hsa04530 Tight junction hsa04670 Leukocyte transendothelial migration |
Reactome |
R-HSA-202733: Cell surface interactions at the vascular wall R-HSA-1474244: Extracellular matrix organization R-HSA-109582: Hemostasis R-HSA-216083: Integrin cell surface interactions |
Summary | |
---|---|
Symbol | JAM2 |
Name | junctional adhesion molecule 2 |
Aliases | VE-JAM; JAM-B; JAMB; CD322; C21orf43; PRO245; VEJAM; JAM-IT/VE-JAM; vascular endothelial junction-associated ...... |
Chromosomal Location | 21q21.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between JAM2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | JAM2 |
Name | junctional adhesion molecule 2 |
Aliases | VE-JAM; JAM-B; JAMB; CD322; C21orf43; PRO245; VEJAM; JAM-IT/VE-JAM; vascular endothelial junction-associated ...... |
Chromosomal Location | 21q21.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of JAM2 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | JAM2 |
Name | junctional adhesion molecule 2 |
Aliases | VE-JAM; JAM-B; JAMB; CD322; C21orf43; PRO245; VEJAM; JAM-IT/VE-JAM; vascular endothelial junction-associated ...... |
Chromosomal Location | 21q21.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of JAM2 in various data sets.
|
Points in the above scatter plot represent the mutation difference of JAM2 in various data sets.
|
Summary | |
---|---|
Symbol | JAM2 |
Name | junctional adhesion molecule 2 |
Aliases | VE-JAM; JAM-B; JAMB; CD322; C21orf43; PRO245; VEJAM; JAM-IT/VE-JAM; vascular endothelial junction-associated ...... |
Chromosomal Location | 21q21.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of JAM2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | JAM2 |
Name | junctional adhesion molecule 2 |
Aliases | VE-JAM; JAM-B; JAMB; CD322; C21orf43; PRO245; VEJAM; JAM-IT/VE-JAM; vascular endothelial junction-associated ...... |
Chromosomal Location | 21q21.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of JAM2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by JAM2. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | JAM2 |
Name | junctional adhesion molecule 2 |
Aliases | VE-JAM; JAM-B; JAMB; CD322; C21orf43; PRO245; VEJAM; JAM-IT/VE-JAM; vascular endothelial junction-associated ...... |
Chromosomal Location | 21q21.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of JAM2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | JAM2 |
Name | junctional adhesion molecule 2 |
Aliases | VE-JAM; JAM-B; JAMB; CD322; C21orf43; PRO245; VEJAM; JAM-IT/VE-JAM; vascular endothelial junction-associated ...... |
Chromosomal Location | 21q21.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of JAM2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | JAM2 |
Name | junctional adhesion molecule 2 |
Aliases | VE-JAM; JAM-B; JAMB; CD322; C21orf43; PRO245; VEJAM; JAM-IT/VE-JAM; vascular endothelial junction-associated ...... |
Chromosomal Location | 21q21.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between JAM2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | JAM2 |
Name | junctional adhesion molecule 2 |
Aliases | VE-JAM; JAM-B; JAMB; CD322; C21orf43; PRO245; VEJAM; JAM-IT/VE-JAM; vascular endothelial junction-associated ...... |
Chromosomal Location | 21q21.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting JAM2 collected from DrugBank database. |
There is no record. |